Scipher Hopes IBD Alliance With Galapagos Is The First Of Many
Executive Summary
Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.
You may also be interested in...
Deal Watch: RedHill Finds New Partner For Movantik
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Biopharma Should Copy Our Gilead Deal, Says Rising Star Galapagos
$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.